Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial
Year: 2025
Type: article
Study design: Clinical Trial
Abstract: Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy : Results from the prospective GHSG-NLG phase II BVB trial
Source: HemaSphere
DOI: 10.1002/hem3.70099
Institutions: Oslo University Hospital, University of Oslo, Uppsala University, University Hospital Cologne, Max Planck Institute for Biology of Ageing, Jena University Hospital, Friedrich Schiller University Jena, Lund University, Aarhus University Hospital, University of Helsinki, Helsinki University Hospital, Heidelberg University, University Hospital Heidelberg, University of Tübingen, Vestre Viken Hospital Trust
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,480
Funder: Takeda Pharmaceutical Company
OpenAlex ID: W4408749461